NASDAQ

OCGN

Ocugen, Inc.
$0.8830CS band Weak

+0.14 (+18.49%) At close · Today 12:49 PM ET

Mkt Cap
$299.4M
Volume
4.8M
52W High
$2.73
52W Low
$0.6909
PE Ratio
—
Avg Vol
6.9M
As of 11/2/26
Div Yield
—
Beta
1.63
As of 11/2/26

Company

Headquarters
Malvern, PA
Employees
116 (2026)
Listed
Dec 3, 2014
Exchange
Nasdaq
Website
ocugen.com
SEC industry
Biological Products, (no Diagnostic Substances)
Cylvex sector
Health Care · Biotech

Biotech

  • Market cap #72 of 146
  • P/B #129 of 131

Ranked highest first among stocks Cylvex covers.

  1. AMGNAmgen Inc$258.8B+3.78%
  2. GILDGilead Sciences Inc$216.6B+4.28%
  3. MRNAModerna Inc$98.52B+8.02%
  4. ARGXargenx SE$57.79B+1.99%
  5. RVMDRevolution Medicines, Inc.$42.45B+1.98%
All Biotech ›

Financial summary

Related companies

About

Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").

From company filings and market data · Not investment advice

Price data

Day Low $0.7650Day High $0.8900
52W Low $0.690952W High $2.73
Open
$0.8110
Prev Close
$0.7452
Volume
4.8M
Avg Vol (30D)
6.9M

From daily bars

Financials

Consensus estimates

The information provided is for educational purposes only and does not constitute investment advice. Past performance does not guarantee future results.